Past, Present, and Future Management of Localized Biliary Tract Malignancies
Most of the patients with gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (iCCA), and peri-hilar cholangiocarcinoma (pCCA) present with advanced disease. Complete staging with multiphasic liver imaging is essential to determine the extent of disease. Operative goals should include a margin-negative resection, portal lymphadenectomy for staging, and sufficient remnant liver volume. Biliary tract malignancies have distinct mutational drivers (GBC and pCCA = ERBB2 in 20%; iCCA = fibroblast growth factor receptor 2 or isocitrate dehydrogenase 1 in 20%) amenable to therapy with inhibitors. Clinical trials assessing neoadjuvant, peri-operative, and adjuvant treatments continue to evolve and now include targeted inhibitors and the integration of hepa tic arterial infusion
Source: Surgical Oncology Clinics of North America - Category: Surgery Authors: Janet Li, Flavio G. Rocha, Skye C. Mayo Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Clinical Trials | Gallbladder Cancer | Liver | Neoadjuvant Therapy | Surgery | Urology & Nephrology